Latest News for: asmd

Edit

Addendum Notice for The Supply, Delivery and Installation of Alternate Internet Connection through Border Gateway Protocol (IFB No. NRB/ASMD/IT/GOODS/NCB/02/080/81) (Nepal Rastra Bank)

Public Technologies 28 Dec 2023
). Nepal Rastra Bank,. Assets and Service Management Department. Baluwatar, Kathmandu. Addendum Notice No. 1 ... 2080/09/13 ... NRB/ASMD/IT/GOODS/NCB/02/080/81) as per the notice published on 2080/08/17 on "Gorkhapatra" national daily newspaper ... B ... C ... IV.
Edit

Damian’s Not-So-Haunted House to raise funds for ASMD treatment

The Signal 23 Oct 2023
By Selvin Ramirez. For The Signal. Welcome, mortals, to Damian’s Not-So-Haunted House ... All donations and bake sale proceeds will benefit the local “Please Save Damian” campaign seeking to develop lifesaving treatment for ASMD, according to Markham ... .
Edit

MOH APPROVES XENPOZYME TO TREAT ASMD - HEALTH DG

Malaysian National News Agency 07 Oct 2023
MOH APPROVES XENPOZYME TO TREAT ASMD - HEALTH DG ... of Xenpozyme (Olipudase alfa 20mg), to treat patients suffering from Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease.
Edit

Treatment of rare genetic condition ASMD now available in UAE

Gulf News 27 Mar 2023
The UAE has become the first country in the Middle East and the fifth in the world to offer treatment for acid sphingomyelinase deficiency (ASMD), a rare genetic disorder that causes premature death.
Edit

UAE is first in the Arab world to treat ASMD

Gulf Daily News 26 Mar 2023
Emirates Health Services (EHS) has provided treatment for a rare genetic condition known as Acid sphingomyelinase deficiency (ASMD) through Al Qassimi Women's & Children's Hospital, one of its facilities. .
Edit

UAE first in Middle East, 5th globally to commence ASMD treatment

Khaleejtimes 26 Mar 2023
The UAE is the first in the Middle East to start the treatment of Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease that causes premature death ... What is ASMD? ... It’s said patients with ASMD ...
Edit

North America Acid Sphingomyelinase Deficiency (ASMD) Market Explosive Growth Opportunity, Latest Trends, Positioning, Potential Benefits ...

MENA FN 14 Oct 2022
(MENAFN - America News Hour) In its market research collateral archive, CRIFAX added a report titled ' North America Acid Sphingomyelinase Deficiency Market, 2023-2033' . This report covers a ... .
Edit

Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Nasdaq Globe Newswire 31 Aug 2022
XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations). �� ... .
Edit

Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) (Sanofi SA)

Public Technologies 31 Aug 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 77049679) .
Edit

Press Release: Xenpozyme� (olipudase alfa) approved by European Commission as first and only treatment for ASMD

Nasdaq Globe Newswire 28 Jun 2022
Xenpozyme� (olipudase alfa) approved by European Commission as first and only treatment for ASMD ... .
Edit

Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD

The Associated Press 28 Jun 2022
Xenpozyme®(olipudasealfa) approved by European Commissionas first and only treatment for ASMD ... About ASMD ... ASMD represents a spectrum of disease, with two types that may represent opposite ends of a continuum referred to as ASMD type A and ASMD type B.
Edit

Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD (Sanofi SA)

Public Technologies 28 Jun 2022
Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD ... ASMD represents a spectrum of disease, with two types that may represent opposite ends of a continuum referred to as ASMD type A and ASMD type B.
Edit

Media Update: CHMP recommends approval of Xenpozyme® (olipudase alfa), the first and only treatment for ASMD (Sanofi SA)

Public Technologies 20 May 2022
). The text version of this document is not available ... Disclaimer ... (noodl. 61680399) .
Edit

Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD

Pharmiweb 10 Feb 2022
About ASMD ... ASMD represents a spectrum of disease caused by the same enzymatic deficiency, with two types that may represent opposite ends of a continuum sometimes referred to as ASMD type A and ASMD type B.
Edit

Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD (Sanofi SA)

Public Technologies 09 Feb 2022
About ASMD ... ASMD represents a spectrum of disease caused by the same enzymatic deficiency, with two types that may represent opposite ends of a continuum sometimes referred to as ASMD type A and ASMD type B.

Article Search

tools

Most Viewed

×
×
×
×